Edition:
United States

Opexa Therapeutics Inc (OPXA.PH)

OPXA.PH on Philadelphia Stock Exchange

4.10USD
20 Jul 2016
Change (% chg)

-- (--)
Prev Close
$4.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
918
52-wk High
$4.70
52-wk Low
$1.83

Latest Key Developments (Source: Significant Developments)

Opexa Therapeutics Q1 loss per share $0.31
Thursday, 12 May 2016 04:01pm EDT 

Opexa Therapeutics Inc : Opexa therapeutics reports first quarter 2016 financial results and provides corporate update .Q1 loss per share $0.31.  Full Article

Opexa Therapeutics, Inc says granting of new t-cell patents covering tcelna
Tuesday, 6 Oct 2015 07:00am EDT 

Opexa Therapeutics, Inc:Says granting of new t-cell patents covering tcelna.  Full Article

Opexa Therapeutics Inc secures private funding
Tuesday, 1 Sep 2015 06:00am EDT 

Opexa Therapeutics Inc:Secures private funding for its nmo orphan development program, including planned phase i/ii clinical study.Says entered into a stock purchase agreement with a private investor to fund the company's nmo program.Stock purchase agreement with a private investor for up to $5 million, upon achievement of certain pre-specified milestones.  Full Article

Opexa Therapeutics Inc amends agreement with Merck Serono
Monday, 9 Mar 2015 07:00am EDT 

Opexa Therapeutics Inc:Says that it has amended its option and license agreement with Merck Serono (a division of Merck, Darmstadt, Germany) and will receive a $3 million payment.Says payment provides support for ongoing phase 2b clinical study of Tcelna((reg))( imilecleucel-T ), Opexa's personalized immunotherapy in development for patients with secondary progressive MS (SPMS), as well as preparation and planning of potential phase 3 studies.  Full Article

Opexa Therapeutics Inc files registration statement for rights offering
Wednesday, 28 Jan 2015 06:05am EST 

Opexa Therapeutics Inc:Says it has filed a registration statement with the Securities and Exchange Commission (SEC) for a proposed rights offering of subscription rights to purchase units comprised of a share of Opexa common stock and warrants to purchase an additional share of Opexa common stock.Says it would distribute one non-transferable subscription right for each share of common stock held on the record date.Says each right would entitle the holder to purchase one unit, composed of one share of common stock and a warrant to purchase one share of common stock, at a subscription price to be determined prior to the effective date of the registration statement.Says it also intends to distribute the non-transferable subscription rights to holders of its Series L warrants who are entitled to participate in the rights offering pursuant to the terms of the warrants held by them.Says it plans to use the proceeds from the rights offering primarily to complete funding the ongoing Phase IIb Abili T clinical study of Tcelna in patients with secondary progressive multiple sclerosis (SPMS) through completion and data release, expected in the H2 2016.  Full Article

Opexa Therapeutics Inc announces termination of public offering of common stock
Tuesday, 16 Sep 2014 08:30am EDT 

Opexa Therapeutics Inc:Has terminated the public offering of shares of its common stock previously announced on Sept. 15.As a result of such termination, no shares will be sold pursuant to the offering.  Full Article

Opexa Therapeutics Inc announces proposed public offering of common stock
Monday, 15 Sep 2014 04:21pm EDT 

Opexa Therapeutics Inc:Intends to offer shares of its common stock in an underwritten public offering.All of the shares in the offering are to be sold by Opexa.The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Intends to use the net proceeds to continue funding the ongoing Abili-T clinical study of Tcelna in patients with Secondary Progressive MS.Uses proceeds to continue preclinical and manufacturing activities for OPX-212 in patients with neuromyelitis optica (NMO), and if such activities are successful, to file an IND application with the FDA to initiate a Phase 1/2 proof-of-concept study.Also uses proceeds for general corporate purposes.Opexa's resources are not adequate to permit completion of these studies, and it will need to secure additional resources to complete these studies and support operations during the course of the trials.Aegis Capital Corp. is acting as sole book-running manager in this offering.  Full Article

Opexa Therapeutics Inc to target rare disease Neuromyelitis Optica (NMO) as next development program
Monday, 8 Sep 2014 07:29am EDT 

Opexa Therapeutics Inc:Says it has commenced development in second indication, Neuromyelitis optica (NMO).Says NMO is rare autoimmune disorder, which is designated as an Orphan disease by U.S. Food and Drug Administration.There is currently no cure and there are no FDA approved therapies for this disease.Initiated preclinical development activities for OPX-212, drug development candidate for NMO, earlier this year and has achieved several regulatory and early development milestones to date.Company is continuing with preclinical development activities with goal of filing an IND with FDA by mid-2015 and then moving into clinical development with phase 1/2 proof-of-concept study.Company believes OPX-212 will qualify for Orphan drug designation and plans also to apply for fast track designation for OPX-212.  Full Article

BRIEF-Opexa Therapeutics Q1 loss per share $0.31

* Opexa therapeutics reports first quarter 2016 financial results and provides corporate update